Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 25;40(5):1365-1379.
doi: 10.13345/j.cjb.230741.

[Advances of CAR-T cell therapy in treating colorectal cancer]

[Article in Chinese]
Zijian Chao  1 , Wenli Liu  1 , Yu Liu  1
Affiliations
Free article
Review

[Advances of CAR-T cell therapy in treating colorectal cancer]

[Article in Chinese]
Zijian Chao et al. Sheng Wu Gong Cheng Xue Bao. .
Free article

Abstract

Globally, colorectal cancer (CRC) ranks as the third most common cancer and the second leading cause of cancer-related fatalities. According to the World Health Organization, there are over 1.9 million annual cases of CRC diagnosed worldwide, resulting in more than 900 000 deaths. In recent years, chimeric antigen receptor T (CAR-T) cell therapy has shown clinical success in treating certain hematological malignancies and is now being explored for its potential in targeting solid tumors like CRC. Currently, CAR-T cell therapies targeting carcinoembryonic antigen (CEA), natural killer group 2, member D ligand (NKG2DL), and other markers have achieved remarkable results in clinical trials, albeit encountering significant challenges. This review summarizes the promising targets of CAR-T cell therapy for CRC and highlights progress made in clinical trials and preclinical studies. Additionally, the review discusses the challenges faced by CAR-T cell therapy in CRC treatment, including a shortage of tumor-specific antigens, cytokine release syndrome, adverse tumor microenvironment, and limited infiltration of CAR-T cells. In summary, this review provides an overview of the latest research progress and challenges in CAR-T cell therapy for CRC, aiming to contribute fresh insights for the clinical treatment of this disease.

Keywords: chimeric antigen receptor T (CAR-T) cell therapy; clinical trials; colorectal cancer; targeted therapy.

PubMed Disclaimer

Similar articles

See all similar articles

MeSH terms

Substances